Asacol 800mg MR Tablets Dosed At 4.8g/Day Herald Fast Symptom Relief And Improved Quality Of Life For reasonably Active UC Patients
Procter & Gamble Pharmaceuticals (NYSE: P&G) announced that Asacol(R) (mesalazine) 800mg Modified Release (MR) tablets are now available in the UK for the treatment of gentle to moderate acute exacerbations of ulcerative colitis (UC), and the maintenance of remission in UC and Crohn’s ileo-colitis patients.1 The ASCEND I and II clinical trials have shown that Asacol 800mg MR tablets at 4.8 g/day supply symptom relief* 10 days faster (median time) than a mesalazine 400mg at 2.
Original post by Dentistry News From Medical News Today
Related Articles
Asacol® 800mg Mr Tablets Approved For Ulcerative Colitis (UC), Maintenance Of Remission Of UC And Crohn’s Ileo-Colitis Asbestos-Induced Lung Cancer Patients Do Not seem To Benefit From Chemotherapy, UK HRT Improves Quality Of Life For Some Staying Active And Drinking reasonably Is The Key To A expanded Life Cancer Survival May Be Predicted By Quality Of Life, U-M Study Finds
No comments yet. Be the first.
Leave a reply
